Sort
48,018 grants matching “immunotherapy”
Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma
$809,915Christine Brown · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
Exploring Siglec-glycan ligand interactions using chemoenzymatic approaches
$809,851Peng Wu · Scripps Research Institute, The · R01 · FY2024 · AI
Exploring Siglec-glycan ligand interactions using chemoenzymatic approaches
$809,851Peng Wu · Scripps Research Institute, The · R01 · FY2023 · AI
Personalized neuroblastoma vaccines
$809,608John M Maris · Children'S Hosp Of Philadelphia · U01 · FY2025 · CA
MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes
$809,466Jill Allison Hollenbach · University Of California, San Francisco · R01 · FY2021 · AI
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer's disease
$809,297Oleg Butovsky · Brigham And Women'S Hospital · R01 · FY2020 · AG
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in AlzheimerâÂÂs disease
$809,297Oleg Butovsky · Brigham And Women'S Hospital · R01 · FY2021 · AG
Discovery of Potent Selective Inhibitors of the Histone Methyltransferase SUV39H1 for the Treatment of Cancer
$809,248Charles H Spruck · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2025 · CA
Discovery of Potent Selective Inhibitors of the Histone Methyltransferase SUV39H1 for the Treatment of Cancer
$809,234Charles H Spruck · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2024 · CA
Regulation of human dendritic cell activation
$809,152Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Role of mouse microbiome in cancer and inflammation
$809,152Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
PEDIATRICS AIDS CLINICAL TRIALS GROUP
$809,086Columbia University Health Sciences · U01 · FY2003 · AI
A STINGing vaccine for TB
$808,927William Ramses Bishai · Johns Hopkins University · R01 · FY2021 · AI
Allogeneic glioma vaccine using TGF-beta knockouts
$808,783Habib Fakhrai · Novarx Corporation · R44 · FY2008 · CA
Protective Human Monoclonal Antibodies to HIV-1
$808,654Susan B Zolla-Pazner · New York University School Of Medicine · R01 · FY2011 · HL
New therapeutics for Shiga toxin-E. coli disease.
$808,403Fumiko Obata · University Of Maryland Baltimore · U01 · FY2011 · AI
Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.
$808,122Christopher Hourigan · National Heart, Lung, And Blood Institute · ZIA · FY2013 · HL
Johns Hopkins Rheumatic Diseases Resource-based Core Center (Johns Hopkins RDRCC)
$807,967Antony Rosen · Johns Hopkins University · P30 · FY2022 · AR
Chemotherapy-free cure of hemoglobin disorders through base editing
$807,747Daniel Evan Bauer · Boston Children'S Hospital · R01 · FY2023 · HL
Immunology of aging and immunotherapy of aging-associated diseases
$807,712Arya Biragyn · National Institute On Aging · ZIA · FY2025 · AG
Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma
$807,680Stephen C Mack · St. Jude Children'S Research Hospital · U01 · FY2023 · CA
Evolution of T cell immunity in blood and tissues over childhood
$807,646Donna L Farber · Columbia University Health Sciences · U01 · FY2023 · AI
Evolution of T cell immunity in blood and tissues over childhood
$807,646Donna L Farber · Columbia University Health Sciences · U01 · FY2024 · AI
Evolution of T cell immunity in blood and tissues over childhood
$807,646Donna L Farber · Columbia University Health Sciences · U01 · FY2025 · AI
Immune Mechanisms, Genetic and Environmental Factors Influencing Outcomes
$807,361Scott H Sicherer · Icahn School Of Medicine At Mount Sinai · U19 · FY2013 · AI